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Abstract Exudative age-related macular degeneration, charac-
terized by choroidal neovascularization (CNV), is a major cause
of visual loss. In this study, we examined the distribution of the
polyion complex (PIC) micelle encapsulating FITC-P(Lys) in
blood and in experimental CNV in rats to investigate whether
PIC micelle can be used for treatment of CNV. We demonstrate
that PIC micelle has long-circulating characteristics, accumu-
lating to the CNV lesions and is retained in the lesion for as
long as 168 h after intravenous administration. These results
raise the possibility that PIC micelles can be used for achieving
e¡ective drug targeting to CNV.
- 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Exudative age-related macular degeneration (AMD), char-
acterized by choroidal neovascularization (CNV), is a major
cause of visual loss in developed countries [1,2]. Photocoagu-
lation of the entire CNV is an e¡ective treatment option for
exudative AMD proved in large randomized control studies
performed by the Macular Photocoagulation Study Group [3].
However, since most CNV extends to the subfovea, perma-
nent central visual loss is inevitable immediately after photo-
coagulation. Thus, alternative treatments for CNV with mini-
mal damage to the healthy retina, such as photodynamic
therapy, are being developed [4]. In addition, compounds with
anti-angiogenic properties are under intensive study for pos-
sible clinical applications [5,6]. Although studies in vivo using
animal CNV models have demonstrated the favorable results
of several anti-angiogenic drugs such as interferon-L and tha-
lidomide, these drugs were not e¡ective in inhibiting the de-
velopment of CNV in humans. To develop a pharmacologi-
cal therapy for CNV with minimal systemic adverse e¡ects,
it is necessary to achieve a high local concentration of the
drug [7].
These results have prompted the search for an alternative
drug delivery system. Macromolecules can accumulate and
prolong their retention in perivascular regions of solid tumors
to a greater extent than in normal tissues because newly
formed vessels in solid tumors exhibit high substance perme-
ability compared with those in normal tissues, and the lymph
systems in tumor tissue are incomplete [8,9]. This e¡ect is
known as the enhanced permeability retention (EPR) e¡ect
[10]. CNV membranes have high permeability and several
studies have demonstrated that macromolecules accumulate
in experimental CNV presumably through the EPR e¡ect
[7].
The size of the molecules is an important factor in exerting
the EPR e¡ect. Polymeric micelles have a size range of several
tens of nanometers with a very narrow distribution, similar to
that of viruses and lipoproteins [8]. Thus, they accumulate in
solid tumors through the EPR e¡ect [11,12]. In addition, com-
pared with the drug delivery system based on macromolecule
conjugates, polymeric micelle can stably encapsulate chemical
compounds with high e⁄ciency [8]. On the basis on this
together with their high drug-loading capacity, polymeric
micelles are expected to become a novel drug delivery sys-
tem. In fact, we have developed a drug delivery system with
polymeric micelles encapsulating doxorubicin [13] and it is
now in phase II clinical trial for the treatment of solid tu-
mors [14].
We have recently developed a novel type of polymeric
micelle formed through electrostatic interaction (polyion com-
plex (PIC) micelle) [8,15]. Unlike polyion complexes formed
from an oppositely charged pair of simple homopolymers
or statistical copolymers, PIC micelles from charged block
copolymers are totally water-soluble and are narrowly dis-
tributed. In this study, to investigate whether PIC micelle
can be used for treatment of CNV, we examined the distri-
bution of the PIC micelle in blood and in experimental CNV
in rats.
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2. Materials and methods
2.1. Animals
Male Brown Norway rats weighing 100^120 g were obtained from
Saitama Animal Lab (Saitama, Japan). All experiments were con-
ducted in accordance with the Animal Care and Use Committee
and the Association for Research in Vision and Ophthalmology State-
ment for the Use of Animals in Ophthalmic and Vision Research.
2.2. Experimental CNV
A general anesthesia was induced with an intraperitoneal injection
(1000 Wl/kg) of a mixture (7:1) of ketamine hydrochloride (Ketalar0,
Sankyo, Tokyo, Japan) and xylazine hydrochloride (Celactal0, Bayer,
Tokyo, Japan) or by inhalation of diethyl ether. The pupil was dilated
with one drop of 0.5% tropicamide (Mydrin0 M, Santen Pharmaceut-
ical, Osaka, Japan) for photocoagulation. Experimental CNV was
created as previously described [16,17]. Fifty laser photocoagulations
were applied to each eye between the major retinal vessels around the
optic disc with a diode laser photocoagulator (DC-30000, Nidek,
Osaka, Japan) and a slit lamp delivery system (SL150, Topcon, To-
kyo, Japan) at a spot size of 75 Wm, duration of 0.05 s, and intensity
of 200 mW.
2.3. Preparation of PIC micelle encapsulating £uorescein
isothiocyanate-labeled poly-L-lysine (Fig. 1)
Fluorescein isothiocyanate-labeled poly-L-lysine [FITC-P(Lys),
100.0 mg; polymerization degree= 105, FITC=0.004 mol/mol of
Lys] and 48.6 mg of polyethylene glycol-block-poly-K,L-aspartic
acid) [PEG-P(Asp); PEG MW=5000 g/mol, polymerization degree
of P(Asp) segment= 78] were dissolved in 10.0 and 5.0 ml of phos-
phate-bu¡ered saline (PBS), respectively. PIC micelle solution was
prepared by mixing the same volume (5.0 ml) of FITC-P(Lys) and
PEG-P(Asp) solutions, in which the molar ratio of Lys and Asp
residues was adjusted to unity. As a control, 5.0 ml of FITC-P(Lys)
solution was diluted in 5.0 ml of PBS. Both PIC micelle and control
solutions included the same concentration (5.0 mg/ml) of FITC-
P(Lys). The average diameter and polydispersity index of PIC micelles
was evaluated by dynamic light scattering (DLS) measured at 25‡C,
using a light scattering spectrophotometer (DLS-7000, Otsuka Elec-
tronics, Osaka, Japan) with a vertically polarized incident beam at
632.8 nm supplied by a He/Ne laser. A scattering angle of 90‡ was
used in this study.
2.4. Accumulation of PIC micelle to CNV lesions: histological analysis
To investigate the accumulation of PIC micelle to the CNV lesions,
50 photocoagulations were applied to the right eye of a total of 23
rats. The left eyes served as non-photocoagulation controls. By tail
injection, 400 Wl of PIC micelle encapsulating 5.0 mg/ml FITC-P(Lys)
or 400 Wl of free FITC-P(Lys) at a concentration of 5.0 mg/ml (n=3)
was administered to rats 7 days after photocoagulation. There was
high mortality in rats receiving FITC-P(Lys) after 1 h, suggesting that
P(Lys) has toxicity.
After the rats were killed with an overdose of sodium pentobarbital,
the eyes were immediately enucleated, snap-frozen in OCT compound
1, 4, 8, 24, and 168 h later for the PIC micelle group (n=4 at each
time point) and 1 h later for the FITC P(Lys) group (n=3). Then
frozen sections were mounted with the ProLong Antifade Kit (Mo-
lecular Probes, Eugene, OR, USA) and observed under a £uorescent
microscope (model IX, Olympus, Tokyo, Japan).
2.5. Measurement of the concentration of PIC micelle in laser-treated
eyes and blood
To investigate the concentration of FITC-P(Lys) in laser-treated
eyes and blood, rats received PIC micelle encapsulating FITC-
Fig. 1. Preparation and schematic structure of PIC micelle encapsulating FITC-P(Lys). PIC micelle consists of an inner complex core formed
by the P(Asp) segment and FITC-P(Lys), and an outer PEG shell.
Fig. 2. DLS histogram of PIC micelle encapsulating FITC-P(Lys).
The average diameter and polydispersity index of PIC micelles were
evaluated by DLS measurement at 25‡C, using a light scattering
spectrophotometer. PIC micelle was narrowly dispersed with a size
around 50.7 nm.
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P(Lys) (n=20) or free FITC-P(Lys) (n=3) intravenously 7 days after
photocoagulation. They were killed with an overdose injection of
sodium pentobarbital 1, 4, 8, 24 and 168 h after receiving the PIC
micelles encapsulating FITC-P(Lys) (n=4 at each time point) and 1 h
after receiving free FITC-P(Lys) (n=3). Immediately after death,
blood samples were collected and the eyes were enucleated. The blood
samples were centrifuged at 12 000 rpm for 5 min and the supernatant
was collected and subjected to spectrophotometric analysis. The reti-
na/choroid was collected after the anterior segment and vitreous were
removed. Then, the retina/choroid samples were homogenized in
0.1 ml of PBS and suspended in a total of 0.3 ml of PBS. The homo-
genates were then centrifuged at 12 000 rpm for 5 min and the super-
natant was collected and subjected to spectrophotometric analysis.
The £uorescence intensity was measured in a £uorescence spectro-
photometer (FP-6500, Jasco, Tokyo, Japan) with an excitation wave-
length of 495 nm and an emission wavelength of 520 nm. The actual
concentration of FITC-P(Lys) was calculated by means of a calibra-
tion curve.
2.6. Statistical analysis
Mann^Whitney’s U-test was used. Values of P6 0.05 were consid-
ered statistically signi¢cant.
3. Results
3.1. Preparation of PIC micelle encapsulating FITC-P(Lys)
Precipitation after mixing FITC-P(Lys) and PEG-P(Asp)
solutions at 25‡C was not observed, even after a period of
over 2 months, suggesting the high storing stability of PIC
micelle. Fig. 2 shows the size distribution of PIC micelle ob-
tained from histogram analysis of DLS measurements. It was
clear that the prepared PIC micelle had a unimodal size dis-
tribution. Also the average diameter and polydispersity index
of PIC micelle were determined to be 50.7 nm and 0.046 by
using the cumulant approach of DLS measurement, indicating
the formation of PIC micelle with an extremely narrow size
distribution.
3.2. Accumulation of PIC micelle to CNV lesions
3.2.1. PIC micelle group. Fluorescent staining was ob-
served in the CNV lesions and also in the choriocapillaris
Fig. 3. Accumulation of PIC micelle to CNV lesion. The frozen sections of the CNV lesions were observed under a £uorescent microscopic 1
(A), 4 (B), 24 (C) and 168 (D) h after rats received PIC micelle-incorporated FITC-P(Lys). Note that FITC-P(Lys) initially di¡uses to the
CNV lesion and choriocapillaris (A,B), and becomes con¢ned to the CNV lesion thereafter (C,D). Bright £uorescence was observed in the
CNV lesions up to 168 h (D). One hour after rats received an intravenous injection of free FITC-P(Lys), FITC-P(Lys) distributes to the CNV
lesion and choriocapillaris (E). Arrowheads in A^E indicate CNV lesions. Most rats died 1 h after free FITC-P(Lys) administration. In the la-
ser-non-treated eyes, £uorescence was observed in the choriocapillaris 1 h after rats received PIC micelle (F) and the £uorescence became invisi-
ble 4 h after the injection of PIC micelle (G). Note that PIC micelle e¡ectively accumulated to the CNV lesion throughout the studied period.
Scale bar, 25 Wm.
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for up to 4 h (Fig. 3A,B). Twenty-four hours after the admin-
istration, accumulation of FITC-P(Lys) to the CNV lesion
was more evident and £uorescence became invisible outside
the photocoagulated lesion including the choroidal and retinal
vasculature (Fig. 3C). The £uorescence was observed for up to
168 h (Fig. 3D). In the non-laser-treated eyes, the £uorescence
was visible in the choroidal vessels for up to 4 h (Fig. 3F), and
the £uorescence became invisible at 24 h and thereafter (Fig.
3G and data not shown). Light microscopic analysis revealed
no abnormalities in other retinal structures.
3.2.2. Free FITC-P(Lys) group. Most rats died 1 h after
the FITC-P(Lys) administration. When evaluated 1 h after
intravenous administration, £uorescence was observed in the
CNV lesion and choriocapillaris (Fig. 3E). In order to reduce
the toxic e¡ect of free FITC-P(Lys), rats received a lower dose
(10 mg per injection) of free FITC-P(Lys). However, all rats
died before 2 h after the administration (ns 10).
3.3. Concentration of FITC-P(Lys) in the laser-treated eyes
3.3.1. PIC micelle group. FITC-P(Lys) was detected in the
retina/choroid from the laser-treated eyes as early as 1 h and
the concentration peaked at 4 h and the residual FITC-P(Lys)
was still evident 168 h after intravenous administration (Fig.
4). The concentration of FITC-P(Lys) was below the detect-
able level in the non-laser-treated eyes.
3.3.2. Free FITC-P(Lys) group. When evaluated 1 h after
intravenous administration, the concentration of FITC-P(Lys)
in the free FITC-P(lys) group was signi¢cantly lower com-
pared to that in the PIC micelle group (Fig. 4).
3.4. Concentration of PIC micelle in blood
Fig. 5 shows the concentration of FITC-P(Lys) in blood
after a single injection of either free FITC-P(Lys) or PIC
micelle encapsulating FITC-P(Lys). The residual amount of
FITC-P(Lys) in blood was 5.0, 7.8, 3.8 and 0.5% of the in-
jected dose at 1, 4, 8, and 24 h, respectively, after intravenous
injection of PIC micelles encapsulating FITC-P(Lys). After
168 h, it was below the detectable level. The concentration
of FITC-P(Lys) in blood was 15% of the injected dose 1 h
after free FITC-P(Lys) injection.
4. Discussion
In this study, FITC-P(Lys) was retained in the CNV lesion
for as long as 168 h after intravenous injection of PIC micelle
encapsulating FITC-P(Lys) as demonstrated by histological
analysis and con¢rmed by the measurement of the concentra-
tion in the retina/choroid of the laser-treated eyes. Because it
was impossible to distinguish free FITC-P(Lys) and FITC-
P(Lys) encapsulated into PIC micelle, the data presented
here do not address whether FITC-P(Lys) was present in a
free form or encapsulated in the PIC micelle. Together with
the high mortality rate associated with free FITC-P(Lys) ad-
ministration, it was not directly proven whether encapsulation
of FITC-P(Lys) into PIC micelle enhanced the accumulation
of FITC-P(Lys) to the CNV lesions throughout the studied
period. However, it was demonstrated that a signi¢cantly
higher amount of FITC-P(Lys) accumulated to the CNV le-
sions 1 h after the injection in the PIC micelle group com-
pared to the free FITC-P(Lys) group. It is of note that the
amount of FITC-P(Lys) in the non-laser-treated eyes was be-
low the detectable level. In addition, because CNVs are highly
permeable similar to the newly formed vessels in solid tumors,
it is plausible to speculate that the PIC micelle is likely to
accumulate to CNV lesions presumably through the EPR ef-
fect. This idea is consistent with recent studies that have dem-
onstrated that macromolecules accumulate in the CNV lesion
in rabbits [18].
We have reported that polymeric micelles have long-circu-
lating characteristics [8] and that the stability of PIC micelles
Fig. 4. Concentration of FITC-P(Lys) in retina/choroid. Concentra-
tions of FITC-P(Lys) in retina/choroid after rats received equivalent
doses of FITC-P(Lys) of PIC micelle-incorporated FITC-P(Lys).
Note that FITC-P(Lys) was detected in retina/choroid from the la-
ser-treated eyes of the PIC micelle group as early as 1 h and the
concentration peaked at 4 h and was still evident 18 h after intrave-
nous administration, whereas the concentration of FITC-P(Lys) in
the free FITC-P(Lys) group was signi¢cantly lower compared to
that in the PIC micelle group 1 h after injection. Most rats died 1 h
after free FITC-P(Lys) administration. Error bars indicate S.D.
Fig. 5. Concentration of PIC micelle in blood. Concentration of
FITC-P(Lys) in blood after rats received 400 Wl of free FITC-P(Lys)
at a concentration of 5.0 mg/ml or 400 Wl of PIC micelles encapsu-
lating 5.0 mg/ml FITC-P(Lys). The residual amount of FITC-P(Lys)
in blood was 5.0, 7.8, 3.8 and 0.5% of the injected dose at 1, 4, 8
and 24 h, respectively, after intravenous injection of PIC micelles
encapsulating FITC-P(Lys). Most rats died 1 h after free FITC-
P(Lys) administration, whereas no rats died after intravenous injec-
tion of PIC micelles encapsulating FITC-P(Lys). Error bars indicate
S.D.
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in the blood stream can be controlled by the charge ratio and
the length of the poly-amino acid, one of the block copoly-
mers that constitute PIC micelles [19]. In this study, 0.5% of
the injected dose was retained in the blood even 24 h after
injection of PIC micelle encapsulating FITC-P(Lys). Gener-
ally, the concentration of compounds in the blood decreases
rapidly to less than 0.1% of the injected dose in a few hours
after intravenous injection of low molecular weight com-
pounds such as £uorescein sodium. In fact, the concentration
of £uorescein sodium 1 h after intravenous injection was at a
non-detectable level (data not shown). Taken together, PIC
micelle encapsulating FITC-P(Lys) also have long-circulating
characteristics, which is a great advantage to exert the EPR
e¡ect.
The concentration of FITC-P(Lys) delivered by PIC micelle
to the retina/choroid peaked 4 h after injection, and remained
as long as 7 days at a concentration higher than 15 Wg/g
protein after only one intravenous injection. Because a total
of 2 mg FITC-P(Lys) was administered, the total amount of
FITC-P(Lys) was approximately 300 ng in the retina/choroid
when it was delivered by PIC micelles. As deduced from these
results, 0.02% of the injected dose accumulated to and was
retained within the retina/choroid for as long as 7 days. In the
blood, 5% and 0.5% of the injected dose were retained 1 and
24 h after the injection of PIC micelle, respectively. Thus, the
FITC-P(Lys) in blood vs. that in the retina/choroid at 1 and
24 h after the injection was 340:1 and 45:1, respectively, sug-
gesting that PIC micelle could be e¡ectively targeted to the
retina/choroid through the EPR e¡ect, in spite of the low
concentrations in blood. Moreover, we found that the admin-
istration of free FITC-P(Lys) was associated with high mor-
tality, whereas administration of PIC micelles encapsulating
FITC-P(Lys) was not. This is in line with previous studies
which demonstrated that modi¢cation of compounds with a
polymeric carrier results in a decreased adverse e¡ect [20]. Our
observation supports that the PIC micelle attenuated the ad-
verse e¡ect, although the underlying cause of this lethal tox-
icity remains to be unraveled. Such characteristics of the PIC
micelle are a great advantage to achieve e¡ective targeting of
drug while reducing systemic adverse e¡ects.
The concentration of PIC micelles increased in the liver and
spleen but gradually decreased in the kidney and lung within
24 h after intravenous injection (data not shown), suggesting
that the PIC micelle is mainly eliminated through the spleen.
In summary, it has been demonstrated that the PIC micelle
e¡ectively accumulates to the CNV lesion. The distribution of
drug-loaded polymeric micelles in the body may be deter-
mined mainly by their size and surface properties and is less
a¡ected by the properties of loaded drugs if they are em-
bedded in the inner core of the micelles. Since PIC micelles
are demonstrated to be able to reserve a variety of drugs,
enzymes [21] and DNA in the core and can serve as non-viral
gene delivery vectors [9,19,22], we believe that PIC micelles
have great potential for achieving e¡ective drug targeting to
CNV.
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